Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Kipps

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Frontiers in Microbiomes|May 28, 2026
Identifying microbial biomarkers of neurodegeneration: a comparative study in Alzheimer's and Parkinson's diseaseSimon De Jaegher, David Pinzauti, Maria D'Aguanno, et al.
The Journal of Prevention of Alzheimer'S Disease|February 14, 2026
Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotesRichard Perry, Christopher Kipps, Maria Eugenia Soto Martín, et al.
The Journal of Prevention of Alzheimer'S Disease|March 14, 2026
Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507]Richard Perry, Christopher Kipps, Maria Eugenia Soto Martín, et al.
BMJ Open|January 23, 2021
Research Evaluation Alongside Clinical Treatment in COVID-19 (REACT COVID-19): an observational and biobanking studyHannah Burke, Anna Freeman, Ahilanandan Dushianthan, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 13, 2025
Lecanemab appropriate use recommendations for clinical practice in the UKCatherine J Mummery, Jill Rasmussen, Dan Blackburn, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Frontiers in Microbiomes|May 28, 2026
Identifying microbial biomarkers of neurodegeneration: a comparative study in Alzheimer's and Parkinson's diseaseSimon De Jaegher, David Pinzauti, Maria D'Aguanno, et al.
The Journal of Prevention of Alzheimer'S Disease|February 14, 2026
Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotesRichard Perry, Christopher Kipps, Maria Eugenia Soto Martín, et al.
The Journal of Prevention of Alzheimer'S Disease|March 14, 2026
Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507]Richard Perry, Christopher Kipps, Maria Eugenia Soto Martín, et al.
BMJ Open|January 23, 2021
Research Evaluation Alongside Clinical Treatment in COVID-19 (REACT COVID-19): an observational and biobanking studyHannah Burke, Anna Freeman, Ahilanandan Dushianthan, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 13, 2025
Lecanemab appropriate use recommendations for clinical practice in the UKCatherine J Mummery, Jill Rasmussen, Dan Blackburn, et al.
Pageof 3